PLYMOUTH, Minn., Aug. 25, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, today announced that it estimates that over 100,000 patients worldwide have been treated using its XprESS Multi-Sinus Dilation System since the launch of the first XprESS product in February 2010.
When used as a stand-alone therapy, Entellus Medical’s balloon sinus dilation products are the only devices proven in a prospective, multicenter, randomized, controlled trial to be as effective as functional endoscopic sinus surgery (FESS). In that trial, patients treated with Entellus Medical products in the ENT physician’s office also experienced faster recovery, less bleeding at discharge, less use of prescription pain medication and fewer post-procedure debridements than patients receiving FESS.
“With the XprESS Multi-Sinus Dilation System, we obtain durable benefits of balloon sinus dilation in a wide group of patients suffering from chronic sinusitis. From my experience, the XprESS family of devices enables the best patient experience in a comfortable and cost-effective office-based setting,” said James D. Gould, MD, FACS, St. Louis Sinus Center.
“The XprESS Multi-Sinus Dilation System provides surgeons with the speed, ease of delivery and efficacy that we need for chronic sinusitis patients,” said Jeffrey M. Gallups, MD, FACS, Ear, Nose, and Throat Institute, Atlanta. “We have used the device for several years and it has consistently performed perfectly.”
“ENT surgeons are becoming increasingly comfortable using our device in lieu of FESS. We believe favorable economics and improved patient outcomes continue to drive a shift of balloon sinus dilation procedures from the operating room into the office setting. Our technologies deliver comfortable and highly efficacious solutions, with faster recovery and reduced costs to both the patient and healthcare system when compared to traditional surgery,” said Robert White, president and CEO of Entellus Medical. “We are excited about our prospects for continued growth of our technologies with patients.”
About Entellus Medical, Inc.
Entellus Medical is a medical technology company focused on the design, development and commercialization of products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room. Its XprESS family of products is used by ENT physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation. When used as a stand-alone therapy, Entellus Medical’s balloon sinus dilation products are the only devices proven in a sufficiently powered prospective, multicenter, randomized, controlled trial to be as effective as FESS. Patients treated with Entellus Medical’s products in this trial in the ENT physician’s office also experienced faster recovery, less bleeding at discharge, less use of prescription pain medication and fewer post-procedure debridements than patients receiving FESS. Entellus Medical currently markets its products in the United States, Europe and Canada and sells its products through a direct sales force in the United States and the United Kingdom.
Forward-Looking Statements:
All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current expectations of Entellus Medical’s management and involve known and unknown risks and uncertainties that may cause the performance of the XprESS Multi-Sinus Dilation System or Entellus Medical’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the prospects for continued growth of Entellus Medical’s technologies with patients. Other factors that could cause actual results to differ materially from those contemplated in this press release can be found under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 filed with the Securities and Exchange Commission (SEC) and its other reports filed with the SEC. Entellus Medical undertakes no obligation to update or revise any forward looking statements, even if subsequent events cause its views to change.
CONTACT: Leigh Salvo 415-513-1281 ir@entellusmedical.com
Help employers find you! Check out all the jobs and post your resume.
